At just 13 years old, Lucas achieved something doctors had never seen before.
At age six, he was diagnosed with diffuse intrinsic pontine glioma (DIPG), one of the deadliest childhood brain tumors, with most patients surviving less than two years.
Lucas joined the BIOMEDE clinical trial in Paris and was treated with everolimus, a drug designed to block pathways involved in tumor growth.
Then something extraordinary happened.
Scan after scan showed the tumor shrinking, until eventually it disappeared completely.
By 2024, Lucas was reported as the first known patient in the world to achieve a complete, lasting response to DIPG, turning a diagnosis once considered almost universally fatal into a medical milestone.
A boy given almost no chance became the case that gave doctors a reason to believe the impossible might not stay impossible forever.
At age six, he was diagnosed with diffuse intrinsic pontine glioma (DIPG), one of the deadliest childhood brain tumors, with most patients surviving less than two years.
Lucas joined the BIOMEDE clinical trial in Paris and was treated with everolimus, a drug designed to block pathways involved in tumor growth.
Then something extraordinary happened.
Scan after scan showed the tumor shrinking, until eventually it disappeared completely.
By 2024, Lucas was reported as the first known patient in the world to achieve a complete, lasting response to DIPG, turning a diagnosis once considered almost universally fatal into a medical milestone.
A boy given almost no chance became the case that gave doctors a reason to believe the impossible might not stay impossible forever.
